Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons

Neurology

Volumn 80, Issue 4, 2013, Pages 371-379

  Crum Cianflone, Nancy F ^a,b   Moore, David J ^c   Letendre, Scott ^c   Roediger, Mollie Poehlman ^a,d   Eberly, Lynn ^a,d   Weintrob, Amy ^a,e   Ganesan, Anuradha ^a,e   Johnson, Erica ^a,f   Rosario, Raechel Del ^a,b   Agan, Brian K ^a   Hale, Braden R ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARMY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION;

ADOLESCENT; ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILITARY PERSONNEL; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84873669536     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827f0776     Document Type: Article

References (33)

1. Heaton RK, Clifford DB, Franklin DR Jr, et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
2. Bhaskaran K, Mussini C, Antinori A, et al; CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008;63:213-221.
3. Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011;52:235-243.
4. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
5. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73:342-348.
6. Heaton RK, Franklin DR, Ellis RJ, et al; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
7. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008;24:1301-1307.
8. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011;52:793-800.
9. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
11. Letendre S, Marquie-Beck J, Capparelli E, et al; CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
12. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502-506.
13. Cherry CL, Wesselingh SL, Lal L, McArther JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005;13:1778-1781.
14. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26:307-319.
15. Heaton RK, Velin RA, McCutchan JA, et al. Neuropsychological impairment in human immunodeficiency virusinfection: implications for employment: HNRC Group. Psychosom Med 1994;56:8-17.
16. Gonzalez R, Heaton RK, Moore DJ, et al; for the HNRC Group. Computerizes reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 2003;9:64-71.
17. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient care, cognitive status, and substance abuse. AIDS 2004;18:S19-S25.
18. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2004;9:355-362.
19. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection: San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997;54:416-424.
20. Heaton RK, Marcotte TD, Mindt MR, et al; HNRC Group. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317-331.
21. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors: multicenter AIDS cohort study. Neurology 1993;43:2245-2252.
22. Sacktor N, Lyles RH, Skolasky R, et al; multicenter AIDS cohort study. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology 2001;56:257-260.
23. Marcotte TD, Deutsch R, McCutchan JA, et al; San Diego HIV Neurobehavioral Research Center (HNRC) Group. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 2003;60:1406-1412.
24. Wallace MR, Nelson JA, McCutchan JA, et al. Symptomatic HIV seroconverting illness is associated with more rapid neurological impairment. Sex Transm Infect 2001; 77:199-201.
25. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011;17: 176-183.
26. Liner KJ II, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 2010;7:85-91.
27. Moore DJ, Letendre SL, Morris S, et al; CHARTER Group. Neurocognitive functioning in acute or early HIV infection. J Neurovirol 2011;17:50-57.
28. Jernigan TL, Archibald SL, Fennema-Notestine C, et al; for the CHARTER Group. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011;17:248-257.
29. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010;16:101-114.
30. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007;8:33-44.
31. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182.
32. Heaton RK, Miller S, Taylor M, Grant I. Revised Comprehensive Norms for an Expanded Halstead-reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Scoring Program. Lutz: Psychological Assessment Resources; 2004.
33. Mapou RL, Kay GG, Rundell JR, Temoshok L. Measuring performance decrements in aviation personnel infected with the human immunodeficiency virus. Aviat Space Environ Med 1993;64:158-164.